Short answer
Altimmune, Inc. (ALT) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$23M
- −15.3% YoY
- EPS (diluted)
- −$0.18
- +30.8% YoY
Source: XBRL data from the Altimmune, Inc. (ALT) Q1 2026 10-Q on SEC EDGAR. USD.
Altimmune, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0 vs $5,000 YoY, down 100%; clinical-stage company without product sales
- Net loss $22.6M vs $19.6M YoY, up 15%; operating loss $24.2M vs $21.8M
- Best R&D line AUD $1.6M, up 393%; worst MASH $3.7M, down 41%
- Cash, equivalents, restricted cash and short-term investments $331.6M; operating cash use $20.9M vs $16.8M
- April offering added $211.2M net proceeds; PERFORMA Phase 3 planned for second half of 2026 amid tariff and inflation risks
Risk Factors
- No material changes from risk factors disclosed in March 6, 2026 Form 10-K
- April 22, 2026 underwriting agreement indicates a subsequent equity financing event
- April 16, 2026 certificate amendment increased authorized shares
- April 24, 2026 common-stock and pre-funded warrants create potential equity dilution risk
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Altimmune, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.